000143658 001__ 143658
000143658 005__ 20240229112602.0
000143658 0247_ $$2doi$$a10.1002/cncr.32160
000143658 0247_ $$2pmid$$apmid:31095726
000143658 0247_ $$2ISSN$$a0008-543X
000143658 0247_ $$2ISSN$$a1045-7410
000143658 0247_ $$2ISSN$$a1097-0142
000143658 0247_ $$2ISSN$$a1934-662X
000143658 0247_ $$2ISSN$$a1934-6638
000143658 0247_ $$2altmetric$$aaltmetric:60716404
000143658 037__ $$aDKFZ-2019-01232
000143658 041__ $$aeng
000143658 082__ $$a610
000143658 1001_ $$0P:(DE-He78)3772dc9cbbc020fbc52b5f63f1dc1e96$$aPulte, Dianne$$b0$$eFirst author$$udkfz
000143658 245__ $$aChanges in population-level survival for advanced solid malignancies with new treatment options in the second decade of the 21st century.
000143658 260__ $$aNew York, NY$$bWiley-Liss$$c2019
000143658 3367_ $$2DRIVER$$aarticle
000143658 3367_ $$2DataCite$$aOutput Types/Journal article
000143658 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1566290170_31933
000143658 3367_ $$2BibTeX$$aARTICLE
000143658 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143658 3367_ $$00$$2EndNote$$aJournal Article
000143658 520__ $$aSeveral new treatments that improve survival in clinical trials have been developed for various solid malignancies in advanced stages. The effect of these options on survival in the general population is currently unknown.Cancers for which 2 or more new treatment options have been approved by the US Food and Drug Administration during the years 2009 through 2011 for the treatment of advanced disease were identified, including adenocarcinoma of the lung, melanoma, breast cancer, prostate cancer, and renal cell carcinoma. Kaplan-Meier analysis was used to compare overall survival for these conditions in the Surveillance, Epidemiology, and End Results database for the periods 2007 to 2008, 2009 to 2010, and 2011 to 2012. Hazard ratios derived from adjusted, shared frailty models for cancer-specific survival were calculated as well for the years of diagnosis (2007-2008, 2009-2010, and 2011-2012).Two-year survival increased for patients with advanced-stage lung adenocarcinoma (+3.0 percentage points), melanoma (+3.4 percentage points), and breast cancer (+2.7 percentage points). When only patients aged 15 to 64 years were included, 2-year survival for those with melanoma increased by +6.7 percentage points. No change in survival was observed for renal cell carcinoma. Decreases in the hazard ratio for cancer-specific mortality were observed during the period 2011 to 2012 compared with 2007 to 2008 for lung adenocarcinoma, melanoma, and breast cancer.Small increases in 2-year survival were observed between the periods 2007 to 2008 and 2011 to 2012 for lung adenocarcinoma, melanoma, and prostate cancer. Cancer-specific mortality decreased for each of these cancers among patients who were diagnosed between the periods 2007 to 2008 and 2011 to 2013. These findings suggest that newer treatment options are beginning to increase survival for stage IV cancers at the population level.
000143658 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000143658 588__ $$aDataset connected to CrossRef, PubMed,
000143658 7001_ $$0P:(DE-He78)bf5409aed74a0923d9402c2c7ad620aa$$aWeberpals, Janick$$b1$$udkfz
000143658 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b2$$udkfz
000143658 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b3$$eLast author$$udkfz
000143658 773__ $$0PERI:(DE-600)1479932-7$$a10.1002/cncr.32160$$gp. cncr.32160$$n15$$p2656-2665$$tCancer$$v125$$x0008-543X$$y2019
000143658 909CO $$ooai:inrepo02.dkfz.de:143658$$pVDB
000143658 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3772dc9cbbc020fbc52b5f63f1dc1e96$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000143658 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bf5409aed74a0923d9402c2c7ad620aa$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000143658 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000143658 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000143658 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000143658 9141_ $$y2019
000143658 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER-AM CANCER SOC : 2017
000143658 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143658 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143658 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000143658 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000143658 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000143658 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143658 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000143658 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143658 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143658 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000143658 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000143658 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000143658 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCER-AM CANCER SOC : 2017
000143658 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lKlinische Epidemiologie und Alternsforschung$$x0
000143658 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000143658 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000143658 980__ $$ajournal
000143658 980__ $$aVDB
000143658 980__ $$aI:(DE-He78)C070-20160331
000143658 980__ $$aI:(DE-He78)C120-20160331
000143658 980__ $$aI:(DE-He78)L101-20160331
000143658 980__ $$aUNRESTRICTED